Objective: To investigate the clinical efficacy and safety of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma.
Methods: The clinical data of 35 patients with lymphoma, including 5 patients of Hodgkin lymphoma and 30 patients of non-Hodgkin lymphoma, who underwent autologous stem cell transplantation after pretreatment with BeEAM regimen from January 2020 to June 2022 in Gansu Provincial Hospital were retrospectively analyzed. Hematopoietic reconstitution, disease outcome after transplantation and the side effects were analyzed.
Results: All 35 patients achieved hematopoietic reconstitution after AHSCT，the median time to neutrophil engraftment was 11 (8-15) days, and the median time to platelet engraftment was 12 (9-17) days. Among the 35 patients, 4 patients died at the end of follow-up, including 3 patients died of lymphoma recurrence or progression and 1 patient died of cerebral hemorrhage. Among 34 patients, 30 had no disease progression at the end of follow-up. The OS rates of patients at 12 and 24 months after transplantation were 90.97% and 90.97%, respectively. The 12 and 24 months PFS rates were 89.64% and 84.92%, respectively. Thiry-five patients underwent grade 3-4 bone marrow suppression. The non-hematological toxicity of BeEAM pretreatment regimen mainly included nausea, vomiting, diarrhea, and oral mucositis, 35 patients experienced nausea and vomiting, but only 4 patients had grade 3-4 nausea and vomiting. Eight patients experienced Grade 1-2 diarrhea. Oral mucositis occurred in 12 patients, including 1 patient of grade 3 oral mucositis. One patient with grade 3 oral mucositis also had grade 3-4 hypokalemia and hypon atremia. 8.6% of patients experienced Grade 1-2 abnormal liver and kidney function. An addition, infectious fever occurred in 18 patients during neutropenia. All patients improved after symptomatic treatment, and there were no transplant-related death.
Conclusion: Bendamustine as a pretreatment regimen for autologous stem cell transplantation in lymphoma is effective, and the side effects are tolerable.
题目: 含苯达莫司汀预处理方案在淋巴瘤自体造血干细胞 移植中的疗效及安全性.
目的: 探讨含苯达莫司汀的BeEAM预处理方案（苯达莫司汀+阿糖胞苷+依托泊苷+美法仑）用于淋巴瘤自体造血干细胞移植的临床疗效及安全性.
方法: 回顾性分析2020年1月至2022年6月甘肃省人民医院行BeEAM预处理方案自体造血干细胞移植的35例淋巴瘤患者的临床资料，其中霍奇金淋巴瘤5例，非霍奇金淋巴瘤30例。分析患者造血重建情况、移植后疾病转归及移植相关不良反应.
结果: 35 例患者均获得造血重建，中性粒细胞植入的中位时间为11（8-15）d，血小板植入的中位时间为12（9-17）d。至随访结束，35例患者中死亡4例，其中3例死于疾病复发或进展，1例死于脑出血。移植前达CR的34例患者中，至随访结束无疾病进展30例。患者移植后 12和24个月总生存率分别为 90.97%和90.97%，12和24个月无进展生存率分别为89.64%和84.92%。35例患者均发生3-4级的骨髓抑制。BeEAM预处理方案的非血液学毒性主要为恶心、呕吐、腹泻、口腔黏膜炎。35例患者均发生恶心、呕吐，但3-4级的恶心呕吐仅有4例；8例发生1-2级腹泻；12例发生口腔黏膜炎，其中1例为3级口腔黏膜炎；1例发生3级口腔黏膜炎的患者同时出现3-4级的低钾低钠血症；肝肾功能异常发生率低（8.6%），均为1-2级。另外，有18例患者粒缺期出现感染性发热，给予对症治疗后所有患者均好转，无移植相关死亡事件发生.
结论: 含苯达莫司汀的方案作为淋巴瘤自体造血干细胞移植的预处理方案临床疗效显著，副作用可以耐受.
Keywords: autologous hematopoietic stem cell transplantation; bendamustine; lymphoma; pretreatment.